NeuroPace Sees Rise in 4Q, Full-Year Sales

Dow Jones

Jan 09, 2025

By Kailyn Rhone

NeuroPace expects to report a rise in fourth quarter and full-year sales.

The Mountain View, Calif.-based medical device company gave preliminary fourth quarter results on Wednesday, and said it forecasts sales of $21 million to $21.5 million, an increase of 17% to 19%.

For the full fiscal year, NeuroPace said it now expects sales of $79.4 million to $79.9 million, up 21% to 22%. It previously guided for full-year sales to be $73 million to $77 million.

Cash and short-term investments as of Dec. 31 are expected to be $52.8 million.

NeuroPace said its Nautilus pivotal trial is on track to complete the required one year follow-up of subjects in March. It also anticipates the data lock and subsequent trial data analysis commencing in the second quarter.

Write to Kailyn Rhone at kailyn.rhone@wsj.com

(END) Dow Jones Newswires

January 08, 2025 17:02 ET (22:02 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2502086035"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502086035\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502086035?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 06:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502086035","market":"hk","top_or_hot":-1,"title":"NeuroPace Sees Rise in 4Q, Full-Year Sales","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kailyn Rhone \n</p>\n<p>\n  NeuroPace expects to report a rise in fourth quarter and full-year sales. \n</p>\n<p>\n  The Mountain View, Calif.-based medical device company gave preliminary fourth quarter results on Wednesday, and said it forecasts sales of $21 million to $21.5 million, an increase of 17% to 19%. \n</p>\n<p>\n  For the full fiscal year, NeuroPace said it now expects sales of $79.4 million to $79.9 million, up 21% to 22%. It previously guided for full-year sales to be $73 million to $77 million. \n</p>\n<p>\n  Cash and short-term investments as of Dec. 31 are expected to be $52.8 million. \n</p>\n<p>\n  NeuroPace said its Nautilus pivotal trial is on track to complete the required one year follow-up of subjects in March. It also anticipates the data lock and subsequent trial data analysis commencing in the second quarter. \n</p>\n<p>\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 17:02 ET (22:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeuroPace Sees Rise in 4Q, Full-Year Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuroPace Sees Rise in 4Q, Full-Year Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-09 06:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kailyn Rhone \n</p>\n<p>\n  NeuroPace expects to report a rise in fourth quarter and full-year sales. \n</p>\n<p>\n  The Mountain View, Calif.-based medical device company gave preliminary fourth quarter results on Wednesday, and said it forecasts sales of $21 million to $21.5 million, an increase of 17% to 19%. \n</p>\n<p>\n  For the full fiscal year, NeuroPace said it now expects sales of $79.4 million to $79.9 million, up 21% to 22%. It previously guided for full-year sales to be $73 million to $77 million. \n</p>\n<p>\n  Cash and short-term investments as of Dec. 31 are expected to be $52.8 million. \n</p>\n<p>\n  NeuroPace said its Nautilus pivotal trial is on track to complete the required one year follow-up of subjects in March. It also anticipates the data lock and subsequent trial data analysis commencing in the second quarter. \n</p>\n<p>\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 17:02 ET (22:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NPCE","symbol_name":"NeuroPace Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2502086035","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502086035","pubTimestamp":1736373720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"NeuroPace expects to report a rise in fourth quarter and full-year sales.The Mountain View, Calif.-based medical device company gave preliminary fourth quarter results on Wednesday, and said it forecasts sales of $21 million to $21.5 million, an increase of 17% to 19%.For the full fiscal year, NeuroPace said it now expects sales of $79.4 million to $79.9 million, up 21% to 22%. It previously guided for full-year sales to be $73 million to $77 million.Cash and short-term investments as of Dec. 31 are expected to be $52.8 million.NeuroPace said its Nautilus pivotal trial is on track to complete the required one year follow-up of subjects in March. It also anticipates the data lock and subsequent trial data analysis commencing in the second quarter.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NPCE":"NeuroPace Inc."},"translate_title":"NeuroPace预计第四季度和全年销售额将增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NPCE":1},"content_text":"By Kailyn Rhone \n\n\n  NeuroPace expects to report a rise in fourth quarter and full-year sales. \n\n\n  The Mountain View, Calif.-based medical device company gave preliminary fourth quarter results on Wednesday, and said it forecasts sales of $21 million to $21.5 million, an increase of 17% to 19%. \n\n\n  For the full fiscal year, NeuroPace said it now expects sales of $79.4 million to $79.9 million, up 21% to 22%. It previously guided for full-year sales to be $73 million to $77 million. \n\n\n  Cash and short-term investments as of Dec. 31 are expected to be $52.8 million. \n\n\n  NeuroPace said its Nautilus pivotal trial is on track to complete the required one year follow-up of subjects in March. It also anticipates the data lock and subsequent trial data analysis commencing in the second quarter. \n\n\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2025 17:02 ET (22:02 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}